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SerologyAbstract Hepatitis B with precore stop codon mutation is related with severe liver damage in
HBeAg negative patients. It is of utmost importance to screen the G1896A precore mutation.
The study was designed to assess the impact of G1986A mutations in patients with different clinical
spectra of the liver disease by PCR–LCR. 210 HBV positive patients with HBeAg negative serology
of different kind of liver diseases (AVH= 72, FH= 21, CH= 79, Cirrhosis = 20 and HCC= 18)
were screened. Patients were screened for the presence or absence of precore G1896A mutation by
PCR–LCR. Direct nucleotide sequencing was done to confirm the results of LCR. Precore mutant
in HCC was 94.4% (17/18), 85.7% (18/21) in FH, 60% (12/20) in liver cirrhosis, 48.1% (38/79) in
chronic hepatitis and 27.7% (20/72) in AVH cases. The serum ALT level was statistically significant
between HBeAg negative WT and G1896A mutants in chronic hepatitis cases. ALT level and HBV
DNA level was slightly raised in the pre core mutant but and was not significant. Genotype D had a
higher prevalence (79.5%) as compared to genotype A (20.5%). The mutations detected by PCR–
LCR were in 100% concordance with direct sequencing. The exceptionally high prevalence ofRiyadh,
gy from
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North India. Saudi Journal of Biological SciG1896A in FH and HCC demonstrates that the precore mutants are strongly associated with the
progression of liver diseases in patients with HBeAg negative serology. The findings are also sug-
gestive of screening HBV precore G1896A mutation particularly in HBeAg negative cases. The pre-
core G1896A mutation increases proportionately in severe form of liver diseases. LCR can be a
suitable tool for screening of G1896A mutations.
 2016 The Authors. Production and Hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatitis B virus (HBV) infection leads to a wide-variety of
clinical manifestations ranging from acute self-limited illness
to different forms of chronic infection progressing to liver fail-
ure in some patients. India is known to be the largest pool of
HBV carriers in the world next to China. There are 43 million
estimated HBV carriers in India (Datta, 2008; Gupta et al.,
2008; Konstantinou et al., 2015). One-third of the patients with
acute hepatitis and two thirds of cases with chronic liver dis-
ease and hepatocellular carcinoma in India are due to HBV
infection. HBV infection is a public health problem in India
and its importance for morbidity and mortality has not been
substantiated (Acharya, 2014).
The prevalence of precore mutants worldwide has been
expressed as 7–30% albeit with wide differences (Schalm
et al., 1990). In Asia, as many as 55% of chronic hepatitis B
patients have a disease, which is sustained by mutant viruses.
A study by (Guptan et al., 1996) has demonstrated that one
fourth of hepatitis B related chronic liver disease in Asian Indi-
ans is due to mutant hepatitis B virus (precore (15.5%) or sur-
face mutant (10.8%) forms). In another study from North
India, prevalence of precore mutant in HBV related chronic
liver diseases is as high as 25.8% and this mutation have found
to be associated with increased severity of liver diseases
(Guptan et al., 1996). Preliminary studies conducted in South
India suggest that G to A switch at nucleotide 1896 is the most
common mutation of HBV genome in patients with chronic
liver disease from the Indian subcontinent. There are also no
data on association of precore mutants with fulminant hepatic
failure and acute failure from this part of the world.
The point mutation involving the pre-core or other regions
can be detected by direct sequencing of the genome, but this
methodology is too costly and time consuming for routine clin-
ical use. An adequately rapid, specific and sensitive method for
detection of this precore G1896A mutant is needed
(Minamitani et al., 1997). Landegreen et al. (1988) reported
an easier method to detect point mutation with ligase enzyme.
Barany (1991) presented a method that uses thermostable
ligase for ligase chain reaction (LCR) based on the theory of
Landegreen. This method of LCR has been successfully used
for the detection of pre-core mutants of HBV (Minamitani
et al., 1997). They have also shown that sensitivity of this
method can be increased by performing LCR on PCR ampli-
fied DNA and the results obtained are comparable with that
of direct sequencing.
With the above background, the current study was designed
to look at the prevalence of precore G1896A mutations in
HBeAg negative serology patients with different kinds of liver
diseases. Also, the effect of mutation in the underlying diseaseet al., Hepatitis B virus precore G1896A
ences (2016), http://dx.doi.org/10.1016/and the sensitivity and specificity of the methods employed for
the detection of mutation.
2. Materials and methods
2.1. Study subjects
A total of HBeAg negative 210 patients (acute viral hepatitis:
72), (fulminant hepatitis: 21), (chronic hepatitis: 79), (liver cir-
rhosis: 20), (hepatocellular carcinoma: 18) who were admitted
in the wards of Lok Nayak Hospital, New Delhi, India were
enrolled in this study with prior informed consent of the
patients. These patients were examined on the basis of history,
clinical examination, liver function profile and various serolog-
ical markers of Hepatitis B (HBsAg, HBeAg, AntiHBc(IgM/
IgG) and AntiHBe) using commercially available ELISA kits
(DIA PRO Diagnostic Bioprobes, Srl., Italy). Upper GI endo-
scopy and ultra sound examination of the patient was done
whenever indicated. The patients enrolled in the study were
regularly followed up at the gastroenterology clinic of our hos-
pital. Prior information about different risk factors such as
intramuscular injections, Intravenous medication, blood trans-
fusions, tattooing and any past history of jaundice in the fam-
ily was collected on a pre-designed questionnaire. The study
was ethically approved by the Institutional Ethics Committee
of Maulana Azad Medical College, New Delhi.
2.2. Extraction of HBV DNA
DNA was extracted by phenol–chloroform method. Briefly, to
the 100 ll of serum 400 ll of distilled water and 500 ll of TE
saturated phenol was added and kept in a water bath for
two hours and centrifuged for 20 min. The supernatant was
added with 500 ll of TE saturated phenol and 200 ll chloro-
form: isoamyl alcohol (24:1) and centrifuged for 10 min at
12,000 rpm. To the supernatant 1/3 volume of ammonium
acetate, 1.5 V of absolute ethanol were added and left over-
night in 40 C. It was then centrifuged for 20 min. The super-
natant was discarded and saturated with 70% ethanol. Pellet
was then dried and suspended in 25 ll of distilled water and
amplified by polymerase chain reaction (PCR).
2.3. Polymerase chain reaction (PCR)
PCR was done in a 50 ll of reaction mixture with primers
HP1: 1771-1790 # 50-TA(C/T) TAG GAG GCT GTA GGC
AT-30 and HP2: 2079-2060 # 50-AGA ATA GCT TGC CTG
AGT GC-30 in a thermo cycler and amplification reaction car-
ried out in 40 cycles of 94 C for 1 min., 55 C for 1 min. and
72 C for 1 min., with a 10 min. extension step at 72 C at themutation in chronic liver disease patients with HBeAg negative serology from
j.sjbs.2016.05.004
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Figure 2 Representative photograph showing detection of HBV
by PCR coupled LCR. Wild type HBV is shown in the left lane
and mutant HBV is shown in the right lane for each patient.
G1896A precore mutation in HBeAg negative serology 3end. 10 ll of the reaction mixture was analysed by elec-
trophoresis in 2% agarose gel that was stained with ethidium
bromide and could detect 309 bp PCR product under UV light
(Fig. 1).
2.4. Ligase chain reaction (LCR)
LCR was performed in the samples, which tested positive for
HBV DNA for the detection of wild virus and mutant virus
(precore mutant with a point mutation from G–A switch at
nucleotide 83 from the precore region) (Fig. 2). The LCR was
carried out to detect the HBV precore G1896A mutants with
the strategy as described by Minamitani et al. (1997). Briefly,
common primers CP1 & CP II each at concentration of
10 mmol/L were 50 end labelled in 25 ll of 50 mmol/L Tris
HCl (ph 8.0), 10 mmol/L MgCl2, T4PNK (NEB), 10 mmol/L
(g-32p) adenosine triphosphate (Board of radiation and isotope
technology, Department of Atomic Energy, Government of
India). The reaction mixture was incubated at 37 C for 1 h
and at 95 C for 10 min. The LCR reaction then took place
in 30 ll reaction mixture with 5 ll of target DNA in 20 mmol
Tris–HCI (pH 7.5) containing 20 mmol KCI, 10 mmol MgCl2,
1 mmol Dithiothreitol, 0.1 mmol ATP, 0.1% NP-40, 4 lg of
herring sperm DNA, 6 U of Pfu ligase (Stratagene, La Jolla,
CA), 20 nmol with each discriminating primers (WS & WA
or MS & MA) and 20 nmol each common primers (CS and
CA). The samples were incubated at 94 C for 1 min. and then
at 60 C for 1 min. and this cycle was repeated a total of 30
times. 10 ll of LCR products were run on 8% polyacrylamide
gel at 175 volts for 2 h. The gel was dried and exposed to X-ray
film for 40 min. at room temperature. The signals generated by
LCR were measured densitometrically (Fig. 2). The sequences
used are as follows: CPI: 50GGG CAT GGA CAT (T/C)
GAC CC(G/T) TAT AAA GAA TTT GGA GC(T/A)(T/A)
C(T/C) G-30; CPII: 50 AAA GCCA(C/T) CCA AGG CAC
AGC TT(G/A) GAG GCT TGA ACA GT(A/G) G-30, WPI:
50-C(T/C) ACT GTT CAA GCC TC (C/T) AAG CTG TGC
CTT GG(G/A) TGG CTT TG-30, WPII: 50-C(A/G) G(A/T)
(A/T) GCT CCA AAT TCT TTA TA(C/A) GGG TC(A/G)
ATG TCC ATG CCCC-3’, MP1: 50-C(T/C) ACT GTT CAA1 2 3 4 5 6 7 8 9 
Figure 1 Representative photographs showing PCR products of
HBV DNA of 309 bp from the precore region. Lane 1: /X174
HaeIII digested marker, Lane 2: negative control and Lanes 3,
4,5,6,7, 8 & 9: Showing samples positive for HBV DNA precore
region.
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TA-30, MPII: 50-C(A/G) G(A/T) (A/T) GCT CCA AAT TCT
TTA TA(C/A)GGG TC(A/G) ATG TCC ATG CCCT-30.
2.5. Nucleotide sequencing
The target PCR products within the agarose gel were purified
for sequencing using the Perfectprep Gel cleanup Kit (Eppen-
dorf, Wetsbuty, NY), according to the manufacturer’s instruc-
tions and then sequenced using 8 l1 of dye terminator from a
DNA sequencing kit (Big Dye Terminator V.3.0 Cycle
Sequencing Ready Reaction, Foster City, CA) on commercial
basis.
2.6. Statistical analysis
Statistics was performed using a Chi square test, Fisher’s exact
test and Mann–Whitney’s U test as appropriate. Data were
expressed as mean ± standard deviation (SD). Difference
was considered significant for p values less than 0.05. The sta-
tistical analysis software used was SPSS software, version 12.0.
3. Results
72 HBV (HBeAg ve) related acute viral hepatitis B were
enrolled in the study (Table. 1). Males constituted 47.2%
(34/72) of the study while females constituted 52.8% (38/72)
of the study. The mean age ± S.D of the patients with acute
viral hepatitis B inducted in the study were 33.06
± 16.36 years. These 72 HBV DNA positive cases were sero-
logically suspected as precore mutants as they had HBsAg pos-
itive, IgMAnti-HBc positive, HBeAg negative, and anti-HBe
positive serology. The precore G1896A mutation was con-
firmed by PCR coupled with LCR in 20 out of 72 (27.7%)Table 1 Prevalence of precore G1896A mutation in HBeAg
negative cases of HBV related patients with the different
spectra of liver diseases as detected by LCR.
Spectrum of liver disease HBV precore
G1896G
(wild)
HBV precore
G1896A (mutant)
Acute viral hepatitis (72) 52 (72.2%) 20 (27.7%)
Fulminant hepatitis (21) 3 (14.3%) 18 (85.7%)
Chronic hepatitis (79) 41 (51.9%) 38 (48.1%)
Liver cirrhosis (20) 8 (40%) 12 (60%)
Hepatocellular carcinoma (18) 1 (5.6%) 17 (94.4%)
mutation in chronic liver disease patients with HBeAg negative serology from
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was further confirmed by direct sequencing. The ALT level
was comparable and statistically non significant between
HBeAg negative WT (272.52 ± 487.128 IU/L) and precore
G1896A (289.57 ± 585.43 IU/L) mutants in AVH cases. The
HBV DNA level (log copies/mL) was also found comparable
and statistically non significant between HBeAg negative WT
(3.4 ± 1.6) and precore G1896A (3.7 ± 1.4) mutants in
AVH cases. Genotype D & A accounted for 79.5% and
20.5% of the cases respectively (Table 2).
21 patients with fulminant hepatitis B (HBeAg ve) were
enrolled in the study (Table 1). Males comprised 10 (47.6%)
of the study while females constituted 11 (52.4%) of the study.
The mean age ± S.D of the patients with fulminant hepatitis B
inducted in the study were 31.08 ± 11.3 years. These 21 cases
were serologically suspected as precore mutants as they had
HBsAg positive, HBcIgM positive, HBeAg negative, and
anti-HBe positive serology. The precore G1896A mutation
was confirmed by PCR coupled with LCR in 18 out of 21
(85.7%) serologically suspicious precore mutant cases (Table 1)
which was further confirmed by direct sequencing. The ALT
level was significantly raised in all the FH cases than the nor-
mal limit but was comparable and statistically non significant
between HBeAg negative WT (1749.66 ± 648.27 IU/L) and
precore G1896A mutant (1272.52 ± 887.128 IU/L) cases.
The HBV DNA level (log copies/mL) was also found compa-
rable and statistically non significant between HBeAg negative
WT (3.76 ± 0.4) and precore G1896A mutants (3.9 ± 1.1).
Totally 79 cases with histologically proven chronic hepatitis
B (HBeAg ve) were enrolled in the study (Table 1). Males
constituted 51 (64.5%) of the study while females constituted
28 (35.5%) of the study. The mean age ± S.D of the patients
with chronic hepatitis B inducted in the study were 34.47
± 13.52 years. These 79 cases were serologically suspected as
precore mutants as they had HBsAg positive, HBcIgG posi-
tive, HBeAg negative, and anti-HBe positive serology. The
precore G1896A mutation was confirmed by PCR coupled
with LCR in 38 out of 79 (48.1%) serologically suspicious pre-
core mutant cases (Table 1) which was further confirmed by
direct sequencing. Significant difference (p< 0.005) was
observed in ALT level of HBeAg negative WT (67.6
± 32.7 IU/L) and precore G1896A (109.82 ± 38.27 IU/L)
mutant chronic hepatitis B cases. The HBV DNA level (log
copies/mL) was found comparable and statistically non signif-
icant between HBeAg negative WT (4.36 ± 1.4) and precore
G1896A mutants (4.9 ± 1.27).
20 HBV related liver cirrhosis (HBeAg ve) were enrolled
in the study (Table 1). Males constituted 16 (80%) whileTable 2 Distribution of HBV genotype among the patients
having different spectra of liver diseases.
Spectrum of liver disease HBV Genotype
A
HBV Genotype
D
Acute viral hepatitis (72) 19.4% (14/72) 80.6% (58/72)
Fulminant hepatitis (21) 19.05% (4/21) 80.95% (17/21)
Chronic hepatitis (79) 21.5% (17/79) 78.5% (62/79)
Liver cirrhosis (20) 20% (4/20) 80% (16/20)
Hepatocellular carcinoma
(18)
22.2% (4/18) 77.8% (14/18)
Total cases (210) 20.5% (43/210) 79.5% (167/210)
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D of the patients with liver cirrhosis inducted in the study were
47.36 ± 16.13 years. These 20 cases were serologically sus-
pected as precore mutants as they had HBsAg positive,
HBcIgG positive, HBeAg negative, and anti-HBe positive
serology. The precore G1896A mutation was confirmed by
PCR coupled with LCR in 12 out of 20 (60%) serologically
suspicious precore mutant cases (Table 1) which was further
confirmed by direct sequencing. The ALT level of precore
G1896A mutant (103.23 ± 98.71 IU/L) cases was slightly
higher than HBeAg negative WT (89.87 ± 92.43 IU/L) but
statistically non significant in liver cirrhosis cases. The HBV
DNA level (log copies/mL) was also found comparable and
statistically non significant between HBeAg negative WT
(5.15 ± 1.36) and precore G1896A mutants (5.36 ± 1.47).
18 hepatocellular carcinoma (HBeAg ve) were enrolled in
the study (Table 1). Males constituted 16 (88.8%) of the study
while females constituted 2 (11.2%) of the study. The mean
age ± S.D of the patients with hepatocellular carcinoma
inducted in the study was 49.23 ± 14.39 years. These 18 cases
were serologically suspected as precore mutants as they had
HBsAg positive, HBcIgG positive, HBeAg negative, and
anti-HBe positive serology. The precore G1896A mutation
was confirmed by PCR coupled with LCR in 17 out of 18
(94.4%) serologically suspicious precore mutant cases (Table 1)
which was further confirmed by direct sequencing. The ALT
level was comparable between HBeAg negative WT (92 IU/
L) and precore G1896A (89.23 ± 78.71 IU/L) mutants in
HCC cases. The HBV DNA level (log copies/mL) was also
found comparable between HBeAg negative WT (5.1) and pre-
core G1896A (5.36 ± 1.47).
G1896A mutation detected by LCR was also confirmed by
direct sequencing. The study suggests that the LCR is 100%
sensitive for the detection of HBV precore G1896A mutation
(Fig. 3).
4. Discussion
HBV continues to be the most important aetiological agent of
acute viral hepatitis, fulminant hepatitis, chronic hepatitis,
liver cirrhosis and hepatocellular carcinoma in the developing
and underdeveloped world. HBV is prone to mutations with
nucleotide substitutions estimated at a rate of 1  105 to
3  105 per site per year (Eloy et al., 2013). Mutations have
been detected in all the regions of the HBV genome but the sig-
nificance of many of these mutations is unclear.
The presence of precore mutations was significantly high
(p< 0.005) in AVH (27.7% 20/72) in comparison to FH
(85.7% 18/21). This suggests that precore mutation may be
one of the important factors for FHF. There is a very limited
data from India on the prevalence and epidemiology of pre-
core mutants. Various studies from the western world have
reported that the precore mutants are responsible for 5–10%
of HBV related liver diseases (Zuccaro et al., 2015), whereas
studies from Japan have reported a much higher frequency
(Imamura et al., 2003). There have been very few studies,
which have looked into the frequency of precore mutants in
patients with acute viral hepatitis and fulminant hepatic fail-
ure. Triki et al. from Tunisia have reported that 40% of
patients with acute viral hepatitis had infection by a mutant
virus (A1896) (Ayed et al., 2007). Minamitani et al. (1997)mutation in chronic liver disease patients with HBeAg negative serology from
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Figure 3 Sequencing chromatogram showing wild type in upper
panel and G1896A mutation in lower.
G1896A precore mutation in HBeAg negative serology 5from Japan, using ligase chain reaction assay reported that
mutant HBV was present in 100% (4/4) of patients with acute
viral hepatitis and 100% (7/7) in patients with fulminant hep-
atic failure. Similarly Singh et al. (2005) from India using
DNA sequencing technique reported the presence of precore/-
core mutants in 100% (5/5) of patients with fulminant hepatic
failure due to HBV which is in contrast with our study where
the precore mutation accounted for 27.7% acute viral hepatitis
cases and 85.7% in fulminant hepatitis cases which were sero-
logically suspected for precore mutants (Khare et al., 2012;
Bhattacharya et al., 2014).
Chronic hepatitis B continues to be the paramount cause of
chronic liver disease in India. The chance of developing pro-
gressive liver disease is higher in subjects with prolonged
replicative phase. Infection of infants and children frequently
leads to persistent HBV carriage with a significant risk for
the development of chronic active hepatitis, cirrhosis and hep-
atocellular carcinoma. Host factors such as age, gender and
immunocompetence, are the main reasons which determine
the outcome of HBV infection. Precore stop codon has also
been associated with severe liver damage in HBeAg negative
individuals in chronic hepatitis B (Sharma et al., 2010;
Ozgenc et al., 2007).
The presence of precore core mutant in 94.4% of HCC
cases demonstrates that precore mutant showed high associa-
tion with HCC. The serum ALT level between HBeAg nega-
tive and wild type was statistically significant but was
insignificant in the other spectrum of liver diseases.
Therefore, it is of immense importance to screen precore
G1896A mutations in patients with HBeAg negative serology
and we have tried to establish LCR as a mutation screening
tool. LCR can act as a useful tool for the management of
hepatitis B virus.Please cite this article in press as: Malik, A. et al., Hepatitis B virus precore G1896A
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has been reported to be associated with severe liver damage in
chronic liver disease patients (Rezende et al., 2005; Arankalle
et al., 2011). A study from North India, showed the prevalence
of precore mutant in chronic liver diseases to be as high as
25.8% and is also associated with increased severity of liver
diseases. Preliminary studies conducted in South India sug-
gests that G to A switch at nucleotide G1896A is a most com-
mon mutation of HBV genome in patients with chronic liver
disease from the Indian subcontinent (Vivekanandan et al.,
2004). Tunisia has reported that precore mutants could be
detected in 65% of HBsAg positive patients with chronic infec-
tion (Ayed et al., 2007). Our results are consistent with those of
studies from Japan that mutations in the core region can be
frequently detected in patients with chronic HBV infections
and that these mutations were more often found in HBeAg
negative patients (Tu et al., 2015). Our study is also in accor-
dance with the study from South India suggesting that the pre-
core and core variants of HBV which are defective in HBeAg
synthesis are relatively more common in Indian patients with
chronic HBV infection (Agarwal et al., 2015).
The survival rate among the patients diagnosed as chronic
hepatitis B was 100% after 5 years. Cirrhosis and hepatocellu-
lar carcinoma are the two major complications of chronic hep-
atitis B infection that incomparably increase the death rate.
The death rate at 5 years was 16% for those with compensated
cirrhosis and 65–86% for decompensated cirrhosis. HBeAg-
negative patients had a higher rate of cirrhosis when compared
with HBeAg-positive patients. Older age and persistent viral
replication are predictors for the development of cirrhosis as
well as mortality.
Various factors involving the host and the virus contribute
to the development of HCC. The rate of mortality was high in
HBeAg negative patients than in HBeAg positive patients in
HCC. Precore mutation accounted for 66.6% (12/20) in Cir-
rhosis and 94.4% (17/18) in HCC. This is also in accordance
with the other studies by Hori et al. (2015) and Barreto et al.
(2015).
Genotypes D and A were the most common genotype
detected HBV associated liver disease patients in India, and
genotype D was the most predominant accounting for 79.5%
of the cases.
Ligase chain reaction was used as a tool for screening
G1896A mutation in all the clinical categories of HBV
patients. The detection of the G1896A mutation or Wild type
samples by LCR was in 100% agreement with the results of
direct sequencing. The usage of ligase chain reaction is com-
paratively more economical, less time consuming and equally
reliable as direct DNA sequencing. However, the use of
radioisotope remains a matter of concern due to its biohaz-
ardous nature. Thus, ligase chain reaction is 100% specific
and sensitive technique when compared with the gold standard
direct sequencing and it can be used very efficiently where a
large population of precore 1896 mutation needs to be
screened.
In conclusion, G1896A precore mutation is highly preva-
lent in patients with HBeAg negative serology in particular
with the clinical categories like FH, CH, Cirrhosis and HCC.
The precore G1896A mutation increases proportionately in
severe form of liver diseases. The exceptionally high prevalence
of G1896A in FH and HCC demonstrates that the precore
mutants are strongly associated with the progression of livermutation in chronic liver disease patients with HBeAg negative serology from
j.sjbs.2016.05.004
6 A. Malik et al.diseases in patients with HBeAg negative serology. This obser-
vation suggests the need of screening HBV precore G1896A
mutation in this region particularly in HBeAg negative cases.
The LCR technology can be a suitable tool for screening
G1896A mutations.
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